These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 29126396)
21. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial. Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719 [TBL] [Abstract][Full Text] [Related]
22. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514 [TBL] [Abstract][Full Text] [Related]
23. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
24. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902 [TBL] [Abstract][Full Text] [Related]
25. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018 [TBL] [Abstract][Full Text] [Related]
26. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684 [TBL] [Abstract][Full Text] [Related]
27. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA; Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481 [TBL] [Abstract][Full Text] [Related]
28. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. D'Alonzo M; Piva E; Pecchio S; Liberale V; Modaffari P; Ponzone R; Biglia N Clin Breast Cancer; 2018 Dec; 18(6):e1361-e1366. PubMed ID: 30122348 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900 [TBL] [Abstract][Full Text] [Related]
30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881 [TBL] [Abstract][Full Text] [Related]
31. Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. Bruno E; Oliverio A; Paradiso A; Daniele A; Tommasi S; Terribile DA; Filippone A; Digennaro M; Pilato B; Danza K; Guarino D; Rossi C; Rossi MM; Venturelli E; Giussani M; Peissel B; Pasanisi P Clin Breast Cancer; 2021 Jun; 21(3):e168-e176. PubMed ID: 33357965 [TBL] [Abstract][Full Text] [Related]
32. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051 [TBL] [Abstract][Full Text] [Related]
33. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers. Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900 [No Abstract] [Full Text] [Related]
34. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791 [TBL] [Abstract][Full Text] [Related]
36. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information. DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341 [TBL] [Abstract][Full Text] [Related]
37. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164 [TBL] [Abstract][Full Text] [Related]
38. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560 [TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
40. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]